1-6 of 6
Martin Barrett
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Glofitamab Plus R-CHOP Induces High Response Rates with a Manageable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A 12-Month Analysis from a Phase Ib Study

Max S. Topp, Monica Tani, Michael Dickinson, Nilanjan Ghosh, Armando Santoro, Antonio Pinto, Francesc Bosch, Christopher P. Fox, Armando Lopez-Guillermo, Thomas Gastinne, Andreas Viardot, William Townsend, Naseer Qayum, Martin Barrett, Derrick Kaufman, Chun Wu, Ronald McCord, Pauline Baumlin, Patrick Kimes, Franck Morschhauser
Journal: Blood
Blood (2023) 142 (Supplement 1): 3085.
https://doi.org/10.1182/blood-2023-174081
Published: 2023
Journal Articles

Glofitamab Plus R-CHOP Induces High Response Rates and a Favorable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Phase Ib Study

Max S. Topp, Monica Tani, Michael Dickinson, Nilanjan Ghosh, Armando Santoro, Antonio Pinto, Francesc Bosch, Christopher P. Fox, Armando López-Guillermo, Claudia Carlucci, Chun Wu, Kathryn Humphrey, Pauline Baumlin, Martin Barrett, Naseer Qayum, Franck Morschhauser
Journal: Blood
Blood (2022) 140 (Supplement 1): 1775–1777.
https://doi.org/10.1182/blood-2022-157732
Published: 2022
Journal Articles

Glofitamab Plus R-CHOP Induces High Response Rates with Minimal Cytokine Release Syndrome (CRS) in Patients (pts) with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and Previously Untreated (1L) Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results from a Dose-Escalation and Safety Run-in Phase Ib Study

Nilanjan Ghosh, William Townsend, Michael Dickinson, Max Topp, Monica Tani, Armando Santoro, Michael Crump, Franck Morschhauser, Steven Le Gouill, Amitkumar Mehta, Anesh Panchal, Chun Wu, Martin Barrett, Kathryn Humphrey, Naseer Qayum, Martin Hutchings
Journal: Blood
Blood (2021) 138 (Supplement 1): 2479.
https://doi.org/10.1182/blood-2021-147780
Published: 2021
Journal Articles

Longer Term Efficacy and Safety of Subcutaneous Compared with Intravenous Rituximab: Updated Results of the Phase 3 SABRINA Study

Andrew J Davies, FRCP PhD, Biljana Mihaljevic, Santiago Mercadal, MD, Georgi Mihaylov, Sirpa Leppä, Denise Cotting, Klaas Veenstra, Artem Zharkov, Mark Dixon, BSc MSC, Martin Barrett, David Macdonald
Journal: Blood
Blood (2016) 128 (22): 1103.
https://doi.org/10.1182/blood.V128.22.1103.1103
Published: 2016
Journal Articles

Pharmacokinetics (PK), Safety and Overall Response Rate (ORR) Achieved with Subcutaneous (SC) Administration of Rituximab in Combination with Chemotherapy Were Comparable to Those Achieved with Intravenous (IV) Administration in Patients (pts) with Follicular Lymphoma (FL) in the First-Line Setting: Stage 1 Results of the Phase III SABRINA Study (BO22334)

Andrew Davies, MD, Francesco Merli, Biljana Mihaljevik, Noppadol Siritanaratkul, MD, Philippe Solal-Céligny, MD, Axel Boehnke, Claude Berge, Christine McIntyre, Martin Barrett, PhD, David Macdonald, MD, FRCPC
Journal: Blood
Blood (2012) 120 (21): 1629.
https://doi.org/10.1182/blood.V120.21.1629.1629
Published: 2012
Journal Articles

Assessment of Minimal Residual Disease (MRD) In Relapsed CLL Patients Treated with Fludarabine and Cyclophosphamide with or without Rituximab (REACH)

Annika Dufour, MD, S. K Bohlander, PhD, Karsten Spiekermann, MD, Stephanie Schneider, Jan Braess, MD, Purvi Kakadiya, Kirsten E Mundt, PhD, Helen Smith, Ming Lin, PhD, Martin Barrett, PhD, Deborah Hurst, MD, Anna Dmoszynska, MD, PhD, Isabelle Bence-Bruckler, MD, FRCPC, Boris V Afanasiev, MD, John Catalano, MBBS, FRACP, FRCPA, Marco Montillo, Christian H. Geisler, MD, Sergey I Moiseev, MD, Philippe Solal-Celigny, MD, Tadeusz Robak, Wolfgang Hiddemann, MD
Journal: Blood
Blood (2010) 116 (21): 1390.
https://doi.org/10.1182/blood.V116.21.1390.1390
Published: 2010